Lineage Cell Therapeutics (LCTX) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, gaining 23.1% versus a loss of 45.2%. Over five years, LCTX leads with a -59.7% price change compared with -97.1% for SABS. SAB Biotherapeutics is the larger company by market cap ($262.0 million vs $239.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | SABS |
|---|---|---|
| Share price | $0.9476 | $2.88 |
| Market cap | $239.66M | $262.04M |
| 1-day change | +1.03% | -1.71% |
| YTD return | -43.26% | -22.99% |
| 1-year return | -45.23% | +23.08% |
| 5-year return | -59.68% | -97.15% |
| EPS (TTM) | $-0.19 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $5.15 |
| 52-week low | $0.88 | $2.10 |
| Distance from 52-week high | -54.66% | -44.08% |
| Average volume | 1.15M | 495.86K |
| Shares outstanding | 252.91M | 90.99M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed LCTX by 68.3 percentage points over the past year.
LCTX vs SABS FAQ
Which is bigger, Lineage Cell Therapeutics or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $262.04M compared with $239.66M for Lineage Cell Therapeutics (LCTX).
Which stock has performed better over the past year, LCTX or SABS?
SABS returned +23.08% over the past 12 months, compared with -45.23% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.